New sleeping pill may treat Alzheimer's

Share this article:

A new insomnia drug may be used for Alzheimer's and depression, according to its Japanese maker.

Takeda Pharmaceutical Co. Ltd., the Osaka-based drug manufacturer, could extend the use of Ramelteon -- a new sleeping pill to be released in the U.S. market in early fall -- to treat Alzheimer's disease and other illnesses. The new drug, which is in clinical trials in Japan and Europe, has a new mechanism that specifically targets the MT1 and MT2 receptors in the brain, which are critical in regulating the body's sleep-wake cycle.

The company filed for FDA approval for the drug last year and expects to gain approval with "non-scheduled drug" status, which means that no restrictions will be placed on how physicians prescribe the drug. It may start clinical development of the drug to treat Alzheimer's disease and depression after the pill's launch, the company announced.

Share this article:

More in News

MedPAC discusses limiting patients' post-acute options

MedPAC discusses limiting patients' post-acute options

Medicare rules might have to be relaxed to give hospitals more say in where patients go for post-acute care, members of the Medicare Payment Advisory Commission proposed at a recent ...

Nursing home workers told not to touch residents due to Ebola concerns

U.S. nursing home workers who hail from West Africa are being stigmatized as potential Ebola carriers and forbidden from touching residents, according to IRIN, an independent news service launched by the United Nations Office for the Coordination of Humanitarian Affairs.

Former office manager charged with embezzling half a million dollars from residents

The former business office manager of a Michigan nursing home has been charged with embezzling more than $460,000 from the resident trust fund, the state's attorney general announced last Thursday.